By streamlining our NGS panels to reflect the fast-growing knowledge of complex gene-disease associations, CENTOGENE’s NGS Panels represent start-of-the-art research – providing fast, thorough, and cost-effective diagnostic solutions for patients and their families.
Diagnosing a genetic disorder often requires analyzing multiple genes. We have designed our NGS panels to simultaneously test multiple genes associated with a particular disorder or group of disorders. Additionally, our panels include all relevant pathogenic and likely pathogenic variants (class 1 and class 2) within coding regions, regulatory sequences, and deep intronic regions. We use all publicly available databases such as HGMD and unpublished variants included in our rare disease-centric Bio/Databank to establish a diagnosis. We provide high-quality sequencing and best-in-class data analysis – interpreted and communicated in comprehensive medical reports.
When choosing one of our NGS panels, your patients will receive high-quality sequencing, best-in-class data analysis and interpretation as well as comprehensive medical reports – significantly simplifying the diagnostic process for you and your patients.
Easy sample submission with CentoCard®
High quality clinical interpretation powered by CENTOGENE’s rare disease-centric Bio/Databank
Quick turnaround time and the strictest quality criteria
User-friendly, online ordering and tracking with CentoPortal®
NGS Panels are recommended for patients meeting any or multiple of the following criteria:*
* Genet Med. 2015 Jun;17(6):444-51. doi: 10.1038/gim.2014.122. Epub 2
Pathogenic and likely pathogenic variants are reported following ACMG classification guidelines. Variants of uncertain significance (VUS) are not reported in any of the following cases: the described phenotype(s) is explained by detected pathogenic or likely pathogenic variant(s); the detected VUS are not related to the described phenotype(s) of the patient or family members; in the lack of sufficient clinical information; and in our oncogenetic panels.
Please note that detailed and specific clinical information (preferentially phenotype/HPOs) is required for variant interpretation and medical diagnosis.
Comprehensive Genetic Testing Across the Cancer Care Management
The targeted approach to detecting myeloid malignancies
BLOC1S1 variants cause lysosomal and autophagic defects resulting in a hypomyelinating leukodystrophy with epileptic encephalopathy
Parkinson’s Disease Publication: African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1.
Publication: Upregulation vs. loss of function of NTRK2 in 44 affected individuals leads to two distinct neurodevelopmental disorders
Our global network of customer support and experts guiding you every step of the way.
Send us a messageRegional Support